<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593606</url>
  </required_header>
  <id_info>
    <org_study_id>SP0908</org_study_id>
    <nct_id>NCT00593606</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine</brief_title>
  <official_title>A Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopathic Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of
      switching from ropinirole therapy to the rotigotine transdermal system and its effect on
      symptoms in subjects with idiopathic Parkinson's disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pulse Rate (Supine, After 1 Minute)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure (Supine, After 1 Minute)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Diastolic Blood Pressure (Supine, After 1 Minute)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pulse Rate (Supine, After 5 Minutes)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure (Supine, After 5 Minutes)</measure>
    <time_frame>Baseline, 28 Days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Diastolic Blood Pressure (Supine, After 5 Minutes)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pulse Rate (Standing, After 1 Minute)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure (Standing, After 1 Minute)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Diastolic Blood Pressure (Standing, After 1 Minute)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pulse Rate (Standing, After 3 Minutes)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure (Standing, After 3 Minutes)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Diastolic Blood Pressure (Standing, After 3 Minutes)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Heart Rate</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PR Interval</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization (beginning of the QRS complex).
Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QRS Duration</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The QRS duration represents the time it takes for ventricular depolarization to occur.
Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QT Interval</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization.
Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization.
Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percentage of Basophilic Granulocytes in White Blood Cell Count</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percentage of Eosinophilic Granulocytes in White Blood Cell Count</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hematocrit</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hemoglobin</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percentage of Lymphocytes in White Blood Cell Count</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percentage of Monocytes in White Blood Cell Count</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percentage of Neutrophilic Granulocytes Segmented in White Blood Cell Count</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Platelet Count</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Red Blood Cell Count</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in White Blood Cell Count</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Albumin</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Alkaline Phosphatase</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Blood Urea Nitrogen</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Calcium</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Chloride</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Creatinine</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Gamma-Glutamyltransferase</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Glucose</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Inorganic Phosphate</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Potassium</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Glutamic Oxaloacetic Transaminase</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Glutamic Pyruvic Transaminase</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Sodium</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Total Bilirubin</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Total Protein</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Uric Acid</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Change = 28 day value minus baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Ears, Eyes, Nose, Mouth, Throat'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Psychiatric'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hematological/Lymphatic Nodes'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Dermatological'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Cardiovascular'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Peripheral Vascular'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Pulmonary'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Musculoskeletal'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hepato-/Gastrointestinal'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Renal/Genitourological'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Metabolic/Endocrine'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Other'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Mental Status'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Deep Tendon Reflexes'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Muscle Strength'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Cranial Nerve Function'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Plantar Reflex'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Gait'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Coordination/Balance'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Involuntary Movements'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Sensory Perception'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Other'</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Completion of Trial From Baseline to End of Treatment</measure>
    <time_frame>Baseline, 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Completion of Trial on the Original Treatment Assignment From Baseline to End of Treatment</measure>
    <time_frame>Baseline, 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drop-out During the 5 Half-life Overlap Period Due to Adverse Events (AEs)</measure>
    <time_frame>Baseline, 2 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drop-out Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period</measure>
    <time_frame>Baseline, 56 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Reduction During the 5 Half-life Overlap Period Due to Adverse Events (AEs)</measure>
    <time_frame>Baseline, 2 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Reduction Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period</measure>
    <time_frame>Baseline, 56 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score From Baseline to End of Treatment</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part I measures 'Mentation, Behavior and Mood'. Range: 0 (Best score possible) to 16 (Worst score possible) Change = 28 day value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score From Baseline to End of Treatment</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part II measures 'Activities in Daily Living'. Range: 0 (Best score possible) to 52 (Worst score possible) Change = 28 day value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part III measures 'Motor Examination'. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 28 day value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score From Baseline to End of Treatment</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part IV measures 'Complications of Therapy'. Range: 0 (Best score possible) to 23 (Worst score possible) Change = 28 day value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Parkinson's Disease Sleep Scale (PDSS) Sum Score From Baseline to End of Treatment</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The PDSS is a scale to assess sleep and nocturnal disability in Parkinson's disease.
Range: 0 (Best score possible) to 60 (Worst score possible) Change = 28 day value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Epworth Sleepiness Scale (ESS) Sum Score From Baseline to End of Treatment</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The ESS is a self-administered questionnaire in which the subject rates the probability of his/her dozing during 8 situations that are differently conductive to sleep Range: 0 (Best score possible) to 24 (Worst score possible) Change = 28 day value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Parkinson's Disease Non-Motor Symptom Assessment Scale (PDNMS) Total Sum Score From Baseline to End of Treatment</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The PDNMS is a rating by the clinician to assess the severity and frequency of non-motor symptoms in Parkinson's disease patients Range: 0 (Best score possible) to 384 (Worst score possible) Change = 28 day value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression (CGI) Item 1 Score From Baseline to End of Treatment</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 1 measures 'Severity of Parkinson's Disease'. Range: 1 (Normal, not ill at all) to 7 (Among the most extremely ill patients) Change = 28 day value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI) Item 2 Score</measure>
    <time_frame>28 days</time_frame>
    <description>The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 2 measures 'Global Improvement'. Range 1 (Very much improved) to 7 (Very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI) Item 3.1</measure>
    <time_frame>28 days</time_frame>
    <description>The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 3.1 measures 'Therapeutic Effect'. Range: 1 (Marked - Vast improvement. Complete or nearly complete remission of all symptoms.) to 4 (Unchanged or worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI) Item 3.2</measure>
    <time_frame>28 days</time_frame>
    <description>The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 3.2 measures 'Therapeutic Side Effects'. Range: 1 (None) to 4 (Outweigh the therapeutic effect)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression (PGI) Item 1 Score</measure>
    <time_frame>28 days</time_frame>
    <description>The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 1 measures 'Global Improvement'. Range: 1 (Very much improved) to 7 (Very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression (PGI) Item 2</measure>
    <time_frame>28 days</time_frame>
    <description>The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 2 measures 'Therapeutic Effect'. Range: 1 (Marked - Vast improvement. Complete or nearly complete remission of all symptoms) to 4 (Unchanged or worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression (PGI) Item 3</measure>
    <time_frame>28 days</time_frame>
    <description>The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 3 measures 'Side Effects'. Range: 1 (I have no side effects) to 4 (They outweigh the therapeutic effect of the trial medication)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short-form Parkinson's Disease Questionnaire (PDQ-8) Single Index Score From Baseline to End of Treatment</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>The PDQ-8 is a self-administered 8-item questionnaire that assesses issues associated with Parkinson's disease.
Range: 0 (good health) to 100 (poor health) Change = 28 day value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Treatment Preference Scale Question 1</measure>
    <time_frame>28 days</time_frame>
    <description>Have you used pharmaceutical treatments for your Parkinson's disease before the study?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Treatment Preference Scale Question 2</measure>
    <time_frame>28 days</time_frame>
    <description>Why did you decide to enter this study?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Treatment Preference Scale Question 3</measure>
    <time_frame>28 days</time_frame>
    <description>In comparing the patch and previous oral treatments for Parkinson's disease, how satisfied have you been with oral medication / patch?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Treatment Preference Scale Question 4</measure>
    <time_frame>28 days</time_frame>
    <description>I would prefer using a patch over taking a pill or capsule for treatment of my Parkinson's disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Treatment Preference Scale Question 5</measure>
    <time_frame>28 days</time_frame>
    <description>I would prefer applying one 40cm**2 patch over applying two 20cm**2 patches for treatment of my Parkinson's disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Treatment Preference Scale Question 6</measure>
    <time_frame>28 days</time_frame>
    <description>What aspects do you like the most about the patch?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Treatment Preference Scale Question 7</measure>
    <time_frame>28 days</time_frame>
    <description>What aspects do you like the least about the patch? Check all that apply.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Rotigotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotigotine</intervention_name>
    <description>Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application</description>
    <arm_group_label>Rotigotine</arm_group_label>
    <other_name>Neupro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is informed and given ample time and opportunity to think about his/her
             participation in this trial and has given his/her written informed consent.

          -  Subject is willing and able to comply with all trial requirements.

          -  Subject is male or female, aged≥ 18 years.

          -  Subject is Korean.

          -  Subjects with idiopathic Parkinson's disease (Hoehn and Yahr Stage I-IV) as defined by
             the cardinal sign, bradykinesia, and at least 1 of the following: resting tremor,
             rigidity, or impairment of postural reflexes.

          -  Subject is not satisfactorily controlled on a total daily dose of ropinirole from 3mg
             to 12mg, inclusive.

          -  If the subject is receiving levodopa, either short-acting or sustained-release (in
             combination with benserazide or carbidopa), the total daily dose must be stable for 28
             days prior to the Baseline Visit and must remain stable for the Treatment Period.

          -  If the subject is receiving an anticholinergic agent (eg, benztropine,
             trihexyphenidyl, parsitan, procyclidine, biperiden), a monoamine oxidase B (MAO-B)
             inhibitor (eg, selegiline), a COMT inhibitor (eg, entacapone), or an
             N-methyl-d-aspartate (NMDA)-antagonist (eg, amantadine), he/she must have been on a
             stable dose for at least 28 days prior to the Baseline Visit and must be maintained on
             that dose for the Treatment Period

        Exclusion Criteria:

        Subjects are not permitted to enroll in the trial if any of the following criteria are met:

          -  Subject has previously participated in a trial with rotigotine.

          -  Subject has participated in another trial of an investigational drug within 28 days
             prior to the Baseline Visit or is currently participating in another trial of an
             investigational drug.

          -  Subject has atypical Parkinsonian syndrome(s), including drug-induced Parkinsonian
             syndrome(s).

          -  Subject has dementia, active psychosis, or hallucinations (not due to antiparkinsonian
             medication).

          -  Subject is receiving therapy with 1 of the following drugs either concurrently or
             within 28 days prior to Baseline Visit: alpha-methyl dopa, metoclopramide, reserpine,
             neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone,
             aripiprazole, clozapine, quetiapine), monoamine oxidase A (MAO-A) inhibitors,
             methylphenidate, or amphetamine.

          -  Subject is currently receiving central nervous system (CNS) active therapy (eg,
             sedatives, hypnotics, antidepressants, anxiolytics), unless the dose has been stable
             for at least 28 days prior to the Baseline Visit and is likely to remain stable for
             the duration of the trial.

          -  Subject has a history of seizures or stroke within 1 year, has had a Transient
             Ischemic Attack (TIA) within 12 months prior to enrollment, or a history of myocardial
             infarction within the last 6 months prior to enrollment.

          -  Presence of clinically relevant hepatic dysfunction.

          -  Presence of clinically relevant renal dysfunction.

          -  Evidence of clinically relevant cardiovascular disorders.

          -  Subject has a QTcB interval of ≥ 500ms at Pretreatment or Baseline (repeated
             measurements within 1 hour).

          -  Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension in the
             6 months prior to Baseline.

          -  Subject has a history of significant skin hypersensitivity to adhesive or other
             transdermals or recent unresolved contact dermatitis.

          -  Subject has malignant neoplastic disease requiring therapy within 12 months prior to
             enrollment.

          -  Subject has a history of chronic alcohol or drug abuse within the last 6 months.

          -  Subject has taken herbal medicine therapy within the last 2 weeks prior to the
             Baseline Visit.

          -  Subject has clinically significant laboratory results that, in the judgment of the
             investigator, would make the subject unsuitable for entry into the trial.

          -  Subject is pregnant or nursing, or is of childbearing potential but (i) not surgically
             sterile or (ii) not using adequate birth control methods (including at least 1 barrier
             method), or (iii) not sexually abstinent or (iv) not at least 2 years postmenopausal.

          -  Subject has evidence of an impulse control disorder according to the Jay Modified
             Minnesota Impulsive Disorders Interview (mMIDI) at Pretreatment (Visit 1).

          -  Subject has any other clinically significant medical or psychiatric condition that
             would, in the judgment of the investigator, interfere with the subject's ability to
             participate in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/SP908_CSS_20080814.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <results_reference>
    <citation>Kim HJ, Jeon BS, Lee WY, Lee MC, Kim JW, Kim JM, Ahn TB, Cho J, Chung SJ, Grieger F, Whitesides J, Boroojerdi B. Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease. BMC Neurol. 2011 Aug 10;11:100. doi: 10.1186/1471-2377-11-100.</citation>
    <PMID>21831297</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <results_first_submitted>December 17, 2008</results_first_submitted>
  <results_first_submitted_qc>April 1, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2009</results_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotigotine</keyword>
  <keyword>NEUPRO</keyword>
  <keyword>Switching trial from ropinirole to rotigotine,</keyword>
  <keyword>safety and tolerability</keyword>
  <keyword>Parkinson disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotigotine</mesh_term>
    <mesh_term>Ropinirole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>124 patients were screened. 5 patients were run-in failures and 3 patients were screen failures. 116 patients started treatment, i.e. were included into the Safety Set. 114 patients were included into the Full Analysis Set. 99 patients completed the treatment period. 2 patients withdrew after the treatment period. 97 patients completed the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rotigotine</title>
          <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Start of Treatment - Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Period Completed</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Run-In Failure</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rotigotine</title>
          <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pulse Rate (Supine, After 1 Minute)</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulse Rate (Supine, After 1 Minute)</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic Blood Pressure (Supine, After 1 Minute)</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (Supine, After 1 Minute)</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Diastolic Blood Pressure (Supine, After 1 Minute)</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure (Supine, After 1 Minute)</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Pulse Rate (Supine, After 5 Minutes)</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulse Rate (Supine, After 5 Minutes)</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic Blood Pressure (Supine, After 5 Minutes)</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 Days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (Supine, After 5 Minutes)</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Diastolic Blood Pressure (Supine, After 5 Minutes)</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure (Supine, After 5 Minutes)</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Pulse Rate (Standing, After 1 Minute)</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulse Rate (Standing, After 1 Minute)</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic Blood Pressure (Standing, After 1 Minute)</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (Standing, After 1 Minute)</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Diastolic Blood Pressure (Standing, After 1 Minute)</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure (Standing, After 1 Minute)</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Pulse Rate (Standing, After 3 Minutes)</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulse Rate (Standing, After 3 Minutes)</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic Blood Pressure (Standing, After 3 Minutes)</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (Standing, After 3 Minutes)</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Diastolic Blood Pressure (Standing, After 3 Minutes)</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure (Standing, After 3 Minutes)</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Heart Rate</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Heart Rate</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in PR Interval</title>
        <description>The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization (beginning of the QRS complex).
Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PR Interval</title>
          <description>The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization (beginning of the QRS complex).
Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in QRS Duration</title>
        <description>The QRS duration represents the time it takes for ventricular depolarization to occur.
Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in QRS Duration</title>
          <description>The QRS duration represents the time it takes for ventricular depolarization to occur.
Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in QT Interval</title>
        <description>The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization.
Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in QT Interval</title>
          <description>The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization.
Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB)</title>
        <description>The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization.
Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB)</title>
          <description>The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization.
Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Percentage of Basophilic Granulocytes in White Blood Cell Count</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Basophilic Granulocytes in White Blood Cell Count</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>Percentage of white blood cell count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Percentage of Eosinophilic Granulocytes in White Blood Cell Count</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Eosinophilic Granulocytes in White Blood Cell Count</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>Percentage of white blood cell count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hematocrit</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hematocrit</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>l/l*100</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>g/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Percentage of Lymphocytes in White Blood Cell Count</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Lymphocytes in White Blood Cell Count</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>Percentage of white blood cell count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="7.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Percentage of Monocytes in White Blood Cell Count</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Monocytes in White Blood Cell Count</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>Percentage of white blood cell count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Percentage of Neutrophilic Granulocytes Segmented in White Blood Cell Count</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Neutrophilic Granulocytes Segmented in White Blood Cell Count</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>Percentage of white blood cell count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Platelet Count</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Platelet Count</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>Giga/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Red Blood Cell Count</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Red Blood Cell Count</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>Tera/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" spread="0.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in White Blood Cell Count</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in White Blood Cell Count</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>Giga/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.045" spread="3.538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Albumin</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Albumin</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>g/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Alkaline Phosphatase</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alkaline Phosphatase</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>Units/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Blood Urea Nitrogen</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Urea Nitrogen</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Calcium</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Calcium</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Chloride</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Chloride</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Creatinine</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Creatinine</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Gamma-Glutamyltransferase</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gamma-Glutamyltransferase</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>Units/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Glucose</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glucose</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Inorganic Phosphate</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inorganic Phosphate</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Potassium</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Potassium</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Glutamic Oxaloacetic Transaminase</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Glutamic Oxaloacetic Transaminase</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>Units/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Glutamic Pyruvic Transaminase</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glutamic Pyruvic Transaminase</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>Units/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Sodium</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sodium</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Bilirubin</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Bilirubin</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.079" spread="1.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Protein</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Protein</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Uric Acid</title>
        <description>Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Uric Acid</title>
          <description>Change = 28 day value minus baseline value.</description>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>µmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.80" spread="35.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Ears, Eyes, Nose, Mouth, Throat’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Ears, Eyes, Nose, Mouth, Throat’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Psychiatric’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Psychiatric’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Hematological/Lymphatic Nodes’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Hematological/Lymphatic Nodes’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Dermatological’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Dermatological’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Cardiovascular’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Cardiovascular’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Peripheral Vascular’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Peripheral Vascular’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Pulmonary’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Pulmonary’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Musculoskeletal’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Musculoskeletal’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Hepato-/Gastrointestinal’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Hepato-/Gastrointestinal’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Renal/Genitourological’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Renal/Genitourological’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Metabolic/Endocrine’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Metabolic/Endocrine’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Other’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for ‘Other’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Mental Status’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Mental Status’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Deep Tendon Reflexes’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Deep Tendon Reflexes’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Muscle Strength’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Muscle Strength’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Cranial Nerve Function’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Cranial Nerve Function’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Plantar Reflex’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Plantar Reflex’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Gait’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Gait’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Coordination/Balance’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Coordination/Balance’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Involuntary Movements’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Involuntary Movements’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Sensory Perception’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Sensory Perception’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Other’</title>
        <time_frame>28 days</time_frame>
        <population>Safety Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for ‘Other’</title>
          <population>Safety Set, only patients with non-missing values were analyzed</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Completion of Trial From Baseline to End of Treatment</title>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Completion of Trial From Baseline to End of Treatment</title>
          <population>Safety Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Completion of Trial on the Original Treatment Assignment From Baseline to End of Treatment</title>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Completion of Trial on the Original Treatment Assignment From Baseline to End of Treatment</title>
          <population>Safety Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Drop-out During the 5 Half-life Overlap Period Due to Adverse Events (AEs)</title>
        <time_frame>Baseline, 2 days</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Drop-out During the 5 Half-life Overlap Period Due to Adverse Events (AEs)</title>
          <population>Safety Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Drop-out Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period</title>
        <time_frame>Baseline, 56 days</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Drop-out Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period</title>
          <population>Safety Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Reduction During the 5 Half-life Overlap Period Due to Adverse Events (AEs)</title>
        <time_frame>Baseline, 2 days</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Reduction During the 5 Half-life Overlap Period Due to Adverse Events (AEs)</title>
          <population>Safety Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Reduction Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period</title>
        <time_frame>Baseline, 56 days</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Reduction Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period</title>
          <population>Safety Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score From Baseline to End of Treatment</title>
        <description>The UPDRS is a scale for the assessment of function in Parkinson’s disease UPDRS Part I measures 'Mentation, Behavior and Mood'. Range: 0 (Best score possible) to 16 (Worst score possible) Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score From Baseline to End of Treatment</title>
          <description>The UPDRS is a scale for the assessment of function in Parkinson’s disease UPDRS Part I measures 'Mentation, Behavior and Mood'. Range: 0 (Best score possible) to 16 (Worst score possible) Change = 28 day value minus baseline value.</description>
          <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score From Baseline to End of Treatment</title>
        <description>The UPDRS is a scale for the assessment of function in Parkinson’s disease UPDRS Part II measures 'Activities in Daily Living'. Range: 0 (Best score possible) to 52 (Worst score possible) Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score From Baseline to End of Treatment</title>
          <description>The UPDRS is a scale for the assessment of function in Parkinson’s disease UPDRS Part II measures 'Activities in Daily Living'. Range: 0 (Best score possible) to 52 (Worst score possible) Change = 28 day value minus baseline value.</description>
          <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment</title>
        <description>The UPDRS is a scale for the assessment of function in Parkinson’s disease UPDRS Part III measures 'Motor Examination'. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment</title>
          <description>The UPDRS is a scale for the assessment of function in Parkinson’s disease UPDRS Part III measures 'Motor Examination'. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 28 day value minus baseline value.</description>
          <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score From Baseline to End of Treatment</title>
        <description>The UPDRS is a scale for the assessment of function in Parkinson’s disease UPDRS Part IV measures 'Complications of Therapy'. Range: 0 (Best score possible) to 23 (Worst score possible) Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score From Baseline to End of Treatment</title>
          <description>The UPDRS is a scale for the assessment of function in Parkinson’s disease UPDRS Part IV measures 'Complications of Therapy'. Range: 0 (Best score possible) to 23 (Worst score possible) Change = 28 day value minus baseline value.</description>
          <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Parkinson’s Disease Sleep Scale (PDSS) Sum Score From Baseline to End of Treatment</title>
        <description>The PDSS is a scale to assess sleep and nocturnal disability in Parkinson’s disease.
Range: 0 (Best score possible) to 60 (Worst score possible) Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Parkinson’s Disease Sleep Scale (PDSS) Sum Score From Baseline to End of Treatment</title>
          <description>The PDSS is a scale to assess sleep and nocturnal disability in Parkinson’s disease.
Range: 0 (Best score possible) to 60 (Worst score possible) Change = 28 day value minus baseline value.</description>
          <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Epworth Sleepiness Scale (ESS) Sum Score From Baseline to End of Treatment</title>
        <description>The ESS is a self-administered questionnaire in which the subject rates the probability of his/her dozing during 8 situations that are differently conductive to sleep Range: 0 (Best score possible) to 24 (Worst score possible) Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Epworth Sleepiness Scale (ESS) Sum Score From Baseline to End of Treatment</title>
          <description>The ESS is a self-administered questionnaire in which the subject rates the probability of his/her dozing during 8 situations that are differently conductive to sleep Range: 0 (Best score possible) to 24 (Worst score possible) Change = 28 day value minus baseline value.</description>
          <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Parkinson’s Disease Non-Motor Symptom Assessment Scale (PDNMS) Total Sum Score From Baseline to End of Treatment</title>
        <description>The PDNMS is a rating by the clinician to assess the severity and frequency of non-motor symptoms in Parkinson’s disease patients Range: 0 (Best score possible) to 384 (Worst score possible) Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Parkinson’s Disease Non-Motor Symptom Assessment Scale (PDNMS) Total Sum Score From Baseline to End of Treatment</title>
          <description>The PDNMS is a rating by the clinician to assess the severity and frequency of non-motor symptoms in Parkinson’s disease patients Range: 0 (Best score possible) to 384 (Worst score possible) Change = 28 day value minus baseline value.</description>
          <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Global Impression (CGI) Item 1 Score From Baseline to End of Treatment</title>
        <description>The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 1 measures 'Severity of Parkinson’s Disease'. Range: 1 (Normal, not ill at all) to 7 (Among the most extremely ill patients) Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Global Impression (CGI) Item 1 Score From Baseline to End of Treatment</title>
          <description>The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 1 measures 'Severity of Parkinson’s Disease'. Range: 1 (Normal, not ill at all) to 7 (Among the most extremely ill patients) Change = 28 day value minus baseline value.</description>
          <population>Full Analysis Set</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression (CGI) Item 2 Score</title>
        <description>The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 2 measures 'Global Improvement'. Range 1 (Very much improved) to 7 (Very much worse)</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression (CGI) Item 2 Score</title>
          <description>The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 2 measures 'Global Improvement'. Range 1 (Very much improved) to 7 (Very much worse)</description>
          <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression (CGI) Item 3.1</title>
        <description>The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 3.1 measures 'Therapeutic Effect'. Range: 1 (Marked – Vast improvement. Complete or nearly complete remission of all symptoms.) to 4 (Unchanged or worse)</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression (CGI) Item 3.1</title>
          <description>The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 3.1 measures 'Therapeutic Effect'. Range: 1 (Marked – Vast improvement. Complete or nearly complete remission of all symptoms.) to 4 (Unchanged or worse)</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Marked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged or Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression (CGI) Item 3.2</title>
        <description>The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 3.2 measures 'Therapeutic Side Effects'. Range: 1 (None) to 4 (Outweigh the therapeutic effect)</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression (CGI) Item 3.2</title>
          <description>The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 3.2 measures 'Therapeutic Side Effects'. Range: 1 (None) to 4 (Outweigh the therapeutic effect)</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Significant Interference with Subj. Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant Interference with Subj. Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outweigh the Theraputic Effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Assessed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression (PGI) Item 1 Score</title>
        <description>The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 1 measures 'Global Improvement'. Range: 1 (Very much improved) to 7 (Very much worse)</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression (PGI) Item 1 Score</title>
          <description>The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 1 measures 'Global Improvement'. Range: 1 (Very much improved) to 7 (Very much worse)</description>
          <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression (PGI) Item 2</title>
        <description>The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 2 measures 'Therapeutic Effect'. Range: 1 (Marked – Vast improvement. Complete or nearly complete remission of all symptoms) to 4 (Unchanged or worse)</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression (PGI) Item 2</title>
          <description>The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 2 measures 'Therapeutic Effect'. Range: 1 (Marked – Vast improvement. Complete or nearly complete remission of all symptoms) to 4 (Unchanged or worse)</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Marked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged or Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing / Not Done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression (PGI) Item 3</title>
        <description>The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 3 measures 'Side Effects'. Range: 1 (I have no side effects) to 4 (They outweigh the therapeutic effect of the trial medication)</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression (PGI) Item 3</title>
          <description>The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time.
Item 3 measures 'Side Effects'. Range: 1 (I have no side effects) to 4 (They outweigh the therapeutic effect of the trial medication)</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Side Effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Significant Interference with Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant Interference with Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outweighing Therapeutic Effect of Trial Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing / Not Done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short-form Parkinson's Disease Questionnaire (PDQ-8) Single Index Score From Baseline to End of Treatment</title>
        <description>The PDQ-8 is a self-administered 8-item questionnaire that assesses issues associated with Parkinson's disease.
Range: 0 (good health) to 100 (poor health) Change = 28 day value minus baseline value.</description>
        <time_frame>Baseline, 28 days</time_frame>
        <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short-form Parkinson's Disease Questionnaire (PDQ-8) Single Index Score From Baseline to End of Treatment</title>
          <description>The PDQ-8 is a self-administered 8-item questionnaire that assesses issues associated with Parkinson's disease.
Range: 0 (good health) to 100 (poor health) Change = 28 day value minus baseline value.</description>
          <population>Full Analysis Set, only patients with non-missing values were analyzed</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Treatment Preference Scale Question 1</title>
        <description>Have you used pharmaceutical treatments for your Parkinson’s disease before the study?</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Treatment Preference Scale Question 1</title>
          <description>Have you used pharmaceutical treatments for your Parkinson’s disease before the study?</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Treatment Preference Scale Question 2</title>
        <description>Why did you decide to enter this study?</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Treatment Preference Scale Question 2</title>
          <description>Why did you decide to enter this study?</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Side effects with oral medicine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral medicine not effective in controlling sympt.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taking med. several times a day was not convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Treatment Preference Scale Question 3</title>
        <description>In comparing the patch and previous oral treatments for Parkinson’s disease, how satisfied have you been with oral medication / patch?</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Treatment Preference Scale Question 3</title>
          <description>In comparing the patch and previous oral treatments for Parkinson’s disease, how satisfied have you been with oral medication / patch?</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Dissatisfied with Oral Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied with Oral Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither Satisfied nor Dissatisfied with Oral Med.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied with Oral Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Satisfied with Oral Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment for Oral Medication Missing / Not Done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Dissatisfied with Patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dissatisfied with Patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither Satisfied nor Dissatisfied with Patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied with Patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Satisfied with Patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment for Patch Missing / Not Done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Treatment Preference Scale Question 4</title>
        <description>I would prefer using a patch over taking a pill or capsule for treatment of my Parkinson’s disease.</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Treatment Preference Scale Question 4</title>
          <description>I would prefer using a patch over taking a pill or capsule for treatment of my Parkinson’s disease.</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither Agree nor Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done / Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Treatment Preference Scale Question 5</title>
        <description>I would prefer applying one 40cm**2 patch over applying two 20cm**2 patches for treatment of my Parkinson’s disease.</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Treatment Preference Scale Question 5</title>
          <description>I would prefer applying one 40cm**2 patch over applying two 20cm**2 patches for treatment of my Parkinson’s disease.</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither Agree nor Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done / Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Treatment Preference Scale Question 6</title>
        <description>What aspects do you like the most about the patch?</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Treatment Preference Scale Question 6</title>
          <description>What aspects do you like the most about the patch?</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Applying the patch once a day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comfortable to wear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Does not interfere with my normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Do not have to take medicine in public</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Provides symptom relief all day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Easy to apply</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Do not have to remember to take med. during day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing / Not Done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Treatment Preference Scale Question 7</title>
        <description>What aspects do you like the least about the patch? Check all that apply.</description>
        <time_frame>28 days</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Rotigotine</title>
            <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Treatment Preference Scale Question 7</title>
          <description>What aspects do you like the least about the patch? Check all that apply.</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hard to apply</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hard to remove</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hard to remove the patch from its pouch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not stay on for the entire day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncomfortable to wear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not always covered by clothing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom relief did not last all day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Done / Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rotigotine</title>
          <description>Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Gait disturbence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Bradykinesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Rapid eye movements sleep abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Libido increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>UCB has &gt; 60 days but &lt;= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB Clinical Trial Call Center</name_or_title>
      <organization>UCB</organization>
      <phone>+1 877 822 9493</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

